Our first-in-class agonist antibody program, BDC-3042, targets the Dectin-2 receptor on tumor-associated macrophages (TAMs) to stimulate anti-tumor immunity. Dectin-2 is an immune-activating pattern recognition receptor that recognizes and induces protective immune responses against fungi and other microbes. It is expressed by TAMs in a broad range of solid tumors, making it an attractive target to enhance anti-tumor immunity through TAM reprogramming. We’ve recently advanced to cohort 6 in our Phase 1 study of BDC-3042 in patients with advanced cancers. Learn more: https://bit.ly/3VunkZR
About us
Bolt Biotherapeutics, Inc., based in the San Francisco Bay Area, is a publicly-traded biotechnology company developing Boltbody™ Immune-stimulating Antibody Conjugates (ISAC), a new class of immuno-oncology therapeutics that have eliminated tumors following systemic administration in preclinical studies and results in the development of immunological memory, which may lead to more durable clinical responses for patients. Bolt’s technology is appropriate for a broad spectrum of antibodies targeting tumor antigens expressed on all types of cancer and therefore applicable to many types of patients, including those who are refractory to the current generation of checkpoint inhibitors. The company is led by a team with extensive oncology drug discovery and development experience. Bolt was founded by Dr. Ed Engleman, and its platform is based on technology exclusively licensed from Stanford University. The company is financed by world-class investors including Novo Holdings, Pivotal bioVenture Partners, Vivo Capital and Nan Fung Life Sciences. For more information about Bolt Biotherapeutics, please visit www.boltbio.com.
- Website
-
http://boltbio.com/
External link for Bolt Biotherapeutics, Inc.
- Industry
- Biotechnology
- Company size
- 51-200 employees
- Headquarters
- REDWOOD CITY, California
- Type
- Public Company
- Founded
- 2015
Locations
-
Primary
Get directions
900 CHESAPEAKE DRIVE
REDWOOD CITY, California 94063, US
Employees at Bolt Biotherapeutics, Inc.
Updates
-
#BoltBio CEO Willie Quinn shares advice and key takeaways four months into his new role. He discusses decision-making, relationship-building, and #leadership. Read his insights below.
Sharing a few thoughts on leadership after my first few months as Bolt CEO
-
September 24th is #WorldCancerResearchDay! Our talented team at #BoltBio is dedicated to the discovery and development of transformative treatments that leverage the immune system for a better way to treat cancer. Learn more about our science: https://bit.ly/3VunkZR
-
-
Our next-generation Boltbody™ ISAC Program, BDC-4182, consists of a Claudin 18.2-targeting antibody that is covalently attached to a novel toll-like receptor (TLR) 7/8 agonist via a non-cleavable linker. Claudin 18.2 is a tight junction protein with expression restricted to the gastric mucosal epithelial cells. As these cells turn malignant, Claudin 18.2 becomes accessible on the tumor-cell surface enabling recognition and binding by BDC- 4182. This expression pattern makes it an excellent target for immune stimulating antibody conjugates (ISACs), which combine the specificity of a tumor-targeting antibody with potent immune stimulation. This approach can target tumors with low Claudin 18.2 expression and lead to long-lasting immunological memory. Learn more about our science: https://bit.ly/3VunkZR
-
-
Meet with #BoltBio management at the Morgan Stanley 22nd Annual Global Healthcare Conference and the H.C. Wainwright & Co., LLC 26th Annual Global Investment Conference next month. We look forward to seeing you. Learn more: https://bit.ly/4g6CgWn
-
-
BDC-4182 is our next-generation Boltbody™ ISAC program targeting Claudin18.2. What makes BDC-4182 a next-generation ISAC? - Outcompetes cytotoxic ADCs in multiple tumor models - Dramatically more active than BDC-1001 with acceptable safety profile - Compelling antitumor activity in IHC1+ tumor models We’re currently preparing BDC-4182 for clinical trials targeting gastric cancer. Learn more about BDC-4182: https://bit.ly/3VunkZR
-
-
Today #BoltBio reported financial results for the second quarter and provided corporate updates. Learn more: https://bit.ly/3WN5AIm
-
-
BDC-3042 is our first-in-class agonist antibody program. It targets Dectin-2 on tumor-associated macrophages (TAMs) for anti-tumor activity. Key features: Dectin-2 is selectively expressed by TAMs in most solid tumors Dectin-2 agonism activates TAMs & elicits anti-tumor activity BDC-3042 activates human TAMs We’re currently evaluating BDC-3042 across seven tumor types in a Phase 1 clinical trial. Learn more about BDC-3042: https://bit.ly/3VunkZR
-
-
Happy #4thofJuly from our team at #BoltBio! We hope that you have a safe and restful holiday! #IndependenceDay
-
-
#BoltBio recognizes and celebrates #Juneteenth, the anniversary of the emancipation of the last enslaved African Americans in the US. Juneteenth is a day for joy, reflection, and action. Not sure what to do in support? Here are a few ideas for consideration. #BlackHistory #Juneteenth #Culture #Inclusivity 𝐀𝐭𝐭𝐞𝐧𝐝 𝐥𝐨𝐜𝐚𝐥 𝐞𝐯𝐞𝐧𝐭𝐬: • Join a local Juneteenth parade or festival or head to Galveston, Texas, to participate in traditional celebrations in the city where, on June 19, 1865, the announcement of General Order No. 3 ended slavery in Texas under the terms of the 1862 Emancipation Proclamation. 𝐒𝐮𝐩𝐩𝐨𝐫𝐭 𝐁𝐥𝐚𝐜𝐤-𝐨𝐰𝐧𝐞𝐝 𝐛𝐮𝐬𝐢𝐧𝐞𝐬𝐬𝐞𝐬: • https://lnkd.in/gNcecPe 𝐕𝐨𝐥𝐮𝐧𝐭𝐞𝐞𝐫: • Share your skills with initiatives that support racial justice such as educational and mentoring programs. • Give time to organizations like the NAACP or local Black community centers. 𝐀𝐫𝐭 𝐚𝐧𝐝 𝐜𝐮𝐥𝐭𝐮𝐫𝐞: • Read books by Black authors, attend art exhibits featuring Black artists, or watch films and plays that highlight Black culture and history. • Visit museums such as the National Museum of African American History and Culture or local African American museums.
-